# Vaxcyte’s stock jumps as pneumococcal vaccine holds its own against Pfizer's, Merck’s shots

> **Open Intelligence Dossier** · First detected: 2026-10-05 19:40 UTC · Category: Business

## Executive Summary
Vaxcyte stock surges following phase 3 trial results for its pneumococcal vaccine candidate in a lucrative market.

## Intelligence Brief
Recent business coverage from outlets including Quartz, Yahoo Finance, TIKR.com, BioSpace, STAT, Barron&amp;#039;s, Investor&amp;#039;s Business Daily, BioPharma Dive, and Fierce Biotech documents significant market movement for Vaxcyte following clinical trial updates. According to the reports, Vaxcyte experienced a substantial stock surge after its lead vaccine candidate, VAX-31, successfully cleared a late-stage test. The phase 3 trial results for the pneumococcal vaccine demonstrate that the shot holds its own against established competitors in the pharmaceutical sector. This development positions the small biotech firm directly against industry heavyweights in a high-stakes arena, drawing intense market attention. The reporting places heavy emphasis on the competitive dynamics within the vaccine sector, noting that the trial data establishes a new benchmark and competitive moat against existing offerings from Pfizer and Merck.


Publications such as TIKR.com and BioPharma Dive describe the clinical outcome as near best-case data, while Barron&amp;#039;s and Investor&amp;#039;s Business Daily highlight the dramatic spikes in share value. The coverage collectively frames this clinical milestone as a direct challenge to the current market share held by larger pharmaceutical companies within a specific multi-billion-dollar therapeutic space. Context provided across the reporting indicates that Vaxcyte is squaring up against Pfizer and Merck in a major market estimated by Investor&amp;#039;s Business Daily to be worth seven billion dollars. The pneumococcal vaccine market represents a lucrative arena where established players have long maintained dominance. Vaxcyte&amp;#039;s lead vaccine candidate, VAX-31, aims to capture a share of this substantial market by demonstrating efficacy comparable to or exceeding current standards set by rival products, though broader contextual details regarding manufacturing capacity and distribution timelines remain to be detailed in future updates.


Looking ahead, coverage does not yet specify the exact dates for regulatory submissions or commercialization schedules, leaving the subsequent trajectory dependent on forthcoming corporate announcements and regulatory interactions. Observers will be monitoring how Pfizer and Merck respond to the new competitive threat, as well as how Vaxcyte manages the commercialization of VAX-31 following this pivotal phase 3 trial success. The ongoing market performance of the company&amp;#039;s stock will also remain a focal point for financial analysts tracking the small biotech&amp;#039;s challenge to industry leaders.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| qz.com | Vaxcyte VAX-31 pneumococcal vaccine phase 3 trial results | [Source Link](https://news.google.com/rss/articles/CBMifEFVX3lxTFBHZlA4SWI3dWJKa2gwaUFLdkY1VGY2cjRZeHIzYVFLZ25lb0xkRGJ4ME1XSEUzcUlNcTIwWDNMTjBidmpNOThnN0lnM2JYdl9XcmpNS0VEMzllS2hSdUMteTg0UlhUOXlweHZlV2tpa3hPdlZBNU9WeFVqdnI?oc=5) |
| Yahoo Finance | NVAX Stock Outruns Moderna As Vaxcyte’s Shot Clears A Late-Stage Test | [Source Link](https://news.google.com/rss/articles/CBMimwFBVV95cUxOX0VscGpydlNCYkVpaFlweDNuRWZBM0NoRlV3XzFPbExHY0dRY0x6UG5qeWNYdHpmaVo4Y2hLdm05MUt6LVFLMFFwYXVGSTlFY3FqdUpYNGtuUlNlRWRLU3E3bjlRUXNaM1o3MEhFa3VNWHFpZk5JUmItZk93aW80LUMzbXUxZ1EydkR4bU0wZXhxaGhIWG5OTzRJaw?oc=5) |
| TIKR.com | Vaxcyte Soars 36% on Phase 3 Pneumococcal Vaccine Win That “Sets a New Benchmark” | [Source Link](https://news.google.com/rss/articles/CBMipwFBVV95cUxNcXl2TGQ4R3lMTF9PazY2NlEzQnRGLU1YU0Z4clNXMFZfWnhCWi15c0owZ0MwTEFXT05LeE9KdU1oSkc3QTN6MDdEZVoxLWpjdEpIWDRKRC1KMjRxcDVaUGgwQUY1ZXcyNHgtdWF0bUdhT0JNVVFHTkJfblQtLVl2SEQ1RnFaNEpDWjdXd25CSTRXelVFLUZTSjFzbXFJOEpFdEMzOHFQUQ?oc=5) |
| BioSpace | Vaxcyte rises as pneumococcal shot establishes ‘new competitive moat’ vs. Pfizer, Merck | [Source Link](https://news.google.com/rss/articles/CBMiwwFBVV95cUxNZUx1ZjVlVUZnOUs1ak85WHMxWFptSW9kUWRaX0JpWEFRcm9EblJTTHRvQ2U0SGVjUkJiU055OXNGd2FnS19GU3U1c25ZQUtuMk1PbS1qZDR6THJkdWM0QUVXMEU1QWRRb0hSWlZZR18wOFdxR3J5SWhHUXBOc3NtbGhTQnNqRVVQSVVRT2dGd0d1WVNWNzFORkk1ckJoc3BnZEx0N3lHOC1sRTUzQm9IVjRRX1ltSTJlU3hkbmExTFN2eEE?oc=5) |
| STAT | Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market | [Source Link](https://news.google.com/rss/articles/CBMijAFBVV95cUxOeEQwUzl0VVhjQjkzdmUyRFA1b0lTb0xWY2FmdVBvdThTMWFJYy1fV2hOYXF3RU5pR3hWbHFUb1VWUjdXd0xLd0R6NG5RMEtsYjZrMml4cy1mNHdyOVo3cVlnQ0JvQUhSMjVXUUxBbmJTRlRTTDMwTVgxd3BXZGF3UlVYX2N2VGVyZ0xvSw?oc=5) |
| Barron's | Vaxcyte Stock Spikes 27% as Lead Vaccine Candidate Takes Aim at Pfizer and Merck | [Source Link](https://news.google.com/rss/articles/CBMiggFBVV95cUxQMU8yUzk3OVpkcEpCRXk0OHd3bmRIR1B3LVMzUnE3TW1mT252d2dCOU85TXJJdXRUSFBqckRnNXgwdlVOMEloVFkyTU9NdDBZWkhkN0ExTWVZcWpoYkQzSVBZcjZmb3VLQ3VZalN5R1dMMWZmS3ZlVkQyQUxZdEk2RjZB?oc=5) |
| Investor's Business Daily | Small Biotech Squares Up To Pfizer, Merck In $7 Billion Market | [Source Link](https://news.google.com/rss/articles/CBMilAFBVV95cUxNNFBEVU83SWZFZ0VNcnM3SFNXZTB1WFF6MEZWN3hVcVZYZkpQUXhIQWFjSWpYM1MwenRiLTJUUW1SNHpUMFlkUkdvVzVtMmxuSHRkN3pGX0JPbnJDZVZYV001NDBKaU1HSjZHRXNzem5yMkJBdjRoaGlNQWlKUlRIdWlhYkxuaXhfbTFnN2FnVEYzUUFv?oc=5) |
| BioPharma Dive | Vaxcyte skyrockets on ‘near best-case’ pneumococcal vaccine data | [Source Link](https://news.google.com/rss/articles/CBMirAFBVV95cUxQZ0xOTUJSV0V1TlpUOExXZzBNanI4WnlSUVNZSE44M2JtMDNoYzBORzN0MEJUSGY4OENxTGtTNWdxbldfWVJLaXc2aTdKRWlYeEUzR0ZLN2sxS21tdzBzZTh1NU9LelBzb0YxMHN0SFhvNXh4YjJTbUlRTENDbkJUV2tBTHRhaHQzSDB2bWtEd0pmQVVVNVdBZUdwaDBvbm5NYlBqbG9sejBWMllR?oc=5) |
| Fierce Biotech | Vaxcyte’s stock jumps as pneumococcal vaccine holds its own against Pfizer's, Merck’s shots | [Source Link](https://news.google.com/rss/articles/CBMivgFBVV95cUxQVV83V2NkTUQ0a3dMTHF1bXVUMkM4OWdMcEd6U3pvVDd4Y25heDlWNUJjX2ItXzZ1X3BMMDdPR2JFLUNOODFxRS0ySFhXQ0lwNWJyamRJRGNad1RnRXl4eHlZd25mMEhlVFRSUzFwZFh4RVNkTXQ2eTNBeFRhZ3d1WldhdTAyNGhlN0M0bC1NWlpOMDZPdER6dldRQi0xNm5UY09FRG9XeDl4cGIzUkxTXzBfdmxXR2ZYUVRzUzR3?oc=5) |

---
*Canonical Source: https://pulse.byoaiapps.com/trend/2026-10-05/vaxcyte-s-stock-jumps-as-pneumococcal-vaccine-holds-its-own-against-pfizer-s*
